当前位置: X-MOL 学术Biochimie › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients?
Biochimie ( IF 3.3 ) Pub Date : 2020-09-10 , DOI: 10.1016/j.biochi.2020.09.003
Pierre Weill 1 , Claire Plissonneau 2 , Philippe Legrand 3 , Vincent Rioux 3 , Ronan Thibault 4
Affiliation  

In around 10% of SARS-CoV-2 infected patients, coronavirus disease-2019 (Covid-19) symptoms are complicated with a severe lung damage called Acute Respiratory Distress Syndrome (ARDS), which is often lethal. ARDS is mainly associated with an uncontrolled overproduction of immune cells and cytokines, called “cytokine storm syndrome”; it appears 7–15 days following the onset of symptoms, leading to systemic inflammation and multiple organ failure. Because they are well-known metabolic precursors of specialized pro-resolving lipid mediators (SPMs), omega-3 long-chain polyunsaturated fatty acids (omega-3 LC-PUFAs) could help improve the resolution of the inflammatory balance, limiting therefore the level and duration of the critical inflammatory period. Omega-3 LC-PUFAs may also interact at different stages of the viral infection, notably on the virus entry and replication. In the absence of demonstrated treatment and while waiting for vaccine possibility, the use of omega-3 LC-PUFAs deserve therefore to be considered, based on previous clinical studies suggesting that omega-3 supplementation could improve clinical outcomes of critically ill patients at the acute phase of ARDS. In this context, it is crucial to remind that the omega-3 PUFA dietary intake levels in Western countries remains largely below the current recommendations, considering both the omega-3 precursor α-linolenic acid (ALA) and long chain derivatives such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). An optimized omega-3 PUFAs status could be helpful to prevent infectious diseases, including Covid-19.



中文翻译:

omega-3脂肪酸饮食补充剂可以帮助减少Covid-19患者的严重并发症吗?

在大约10%的SARS-CoV-2感染患者中,冠状病毒病-2019(Covid-19)症状与称为急性呼吸窘迫综合征(ARDS)的严重肺损伤并发,这通常是致命的。急性呼吸窘迫综合征主要与免疫细胞和细胞因子不受控制的过度生产有关,称为“细胞因子风暴综合症”。症状发作后7-15天出现,导致全身性炎症和多器官功能衰竭。因为它们是特殊的亲分解脂质介体(SPM)的众所周知的代谢前体,所以omega-3长链多不饱和脂肪酸(omega-3 LC-PUFAs)可以帮助改善炎症平衡的分辨率,因此限制了其水平和关键炎症期的持续时间。Omega-3 LC-PUFAs也可能在病毒感染的不同阶段相互作用,特别是关于病毒的进入和复制。根据先前的临床研究表明,在没有经过证实的治疗的情况下,并且在等待疫苗可能性的同时,应考虑使用omega-3 LC-PUFA,建议补充omega-3可以改善重症患者在急性期的临床疗效阶段的ARDS。在这种情况下,至关重要的是要提醒西方国家,考虑到omega-3前体α-亚麻酸(ALA)和长链衍生物(如二十碳五烯酸),omega-3 PUFA的饮食摄入水平仍大大低于当前建议。 (EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。在没有经过证实的治疗的情况下,并且在等待疫苗的可能性时,基于先前的临床研究表明,应补充使用omega-3 LC-PUFA,这表明补充omega-3可以改善重症患者在急性期的临床结果。阶段的ARDS。在这种情况下,至关重要的是要提醒西方国家,考虑到omega-3前体α-亚麻酸(ALA)和长链衍生物(如二十碳五烯酸),omega-3 PUFA的饮食摄入水平仍大大低于当前建议。 (EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。在没有经过证实的治疗的情况下,并且在等待疫苗的可能性时,基于先前的临床研究表明,应补充使用omega-3 LC-PUFA,这表明补充omega-3可以改善重症患者在急性期的临床结果。阶段的ARDS。在这种情况下,至关重要的是要提醒西方国家,考虑到omega-3前体α-亚麻酸(ALA)和长链衍生物(如二十碳五烯酸),omega-3 PUFA的饮食摄入水平仍大大低于当前建议。 (EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。根据先前的临床研究表明,补充omega-3可以改善ARDS急性期危重患者的临床结局。在这种情况下,至关重要的是要提醒西方国家,考虑到omega-3前体α-亚麻酸(ALA)和长链衍生物(如二十碳五烯酸),omega-3 PUFA的饮食摄入水平仍大大低于当前建议。 (EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。根据先前的临床研究表明,补充omega-3可以改善ARDS急性期危重患者的临床结局。在这种情况下,至关重要的是要提醒西方国家,考虑到omega-3前体α-亚麻酸(ALA)和长链衍生物(如二十碳五烯酸),omega-3 PUFA的饮食摄入水平仍大大低于当前建议。 (EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。同时考虑omega-3前体α-亚麻酸(ALA)和长链衍生物,如二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。同时考虑omega-3前体α-亚麻酸(ALA)和长链衍生物,如二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)。优化的omega-3 PUFA状态可能有助于预防包括Covid-19在内的传染病。

更新日期:2020-09-10
down
wechat
bug